![Cell Source, Inc. logo](/logos/CLCS.webp)
Cell Source, Inc.
OTC:CLCS
Overview | Financials
Company Name | Cell Source, Inc. |
Symbol | CLCS |
Currency | USD |
Price | 0.498 |
Market Cap | 19,002,311 |
Dividend Yield | 0% |
52-week-range | 0 - 1.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Itamar Shimrat |
Website | https://www.cell-source.com |
An error occurred while fetching data.
About Cell Source, Inc.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD